Table of Contents
- Latest Results
- EXECUTIVE SUMMARY
- Introduction
- Current Financial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued R&D Projects
- Other Factors Affecting The Bottom Line
- Conclusions/Outlook
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CARDIO VASCULAR AND METABOLIC DISEASES
- Marketed Products
- Avapro/Avalide
- Plavix/Iscover
- Others
- R&D Projects
- Apixaban
- Dapagliflozin
- KAI-9803
- Onglyza
- SLV319
- Growth Forecast
- VIROLOGY
- Marketed Products
- Atripla
- Baraclude
- Reyataz
- Sustiva
- Others
- R&D Projects
- Growth Forecast
- NEUROSCIENCE
- Marketed Products
- R&D Projects
- Growth Forecast
- ONCOLOGY
- Marketed Products
- Erbitux
- Ixempra
- Sprycel
- Others
- R&D Projects
- Angiocept
- BMS-184476
- BMS-214662
- BMS-247616
- BMS-275291
- BMS-66513
- Discodermolide
- Elotuzumab
- Ipilimumab
- XL413
- Growth Forecast
- IMMUNOLOGY
- Marketed Products
- R&D Projects
- Belatacept
- BMS-347070
- BMS-582949
- P5540446
- Growth Forecast
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- AMRI Inc.
- Aspen Pharmacare/Emcure Pharmaceuticals
- AstraZeneca
- Biocon
- Celltrion Inc
- Chiron Corporation
- Dainippon Sumitomo Pharma
- Domantis Inc
- Elan Corporation Plc
- Elixir Pharmaceuticals
- Exelixis Inc
- Gilead Sciences Inc
- GPC Biotech Inc
- ImClone Systems
- Intra-Cellular Therapies Inc (ICT)
- Isis Pharmaceuticals
- Kai Pharmaceuticals Inc
- Lexicon Genetics Inc
- Lion Corporation
- Medarex Inc
- Merck KGaA
- Merck Sante SAS
- Nerviano Medical Sciences
- Nissan Chemical Industries Ltd/Teijin Pharma Ltd.
- Otsuka/Taiho Pharmaceutical Co Ltd.
- PDL BioPharma Inc
- Pfizer
- Pharmacopeia Inc
- sanofi-aventis
- Shionogi
- Sunesis Pharmaceuticals
- XDx Inc
- ZymoGenetics Inc
- APPENDIX 4 - INFRASTRUCTURE
- Research And Development Facilities
- Manufacturing Facilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint-venture Companies
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Business Segment
- Sales By Business Segment
- Year-End Assets By Business Segment
- Sales By Geographic Area (Origin)
- Year-End Assets By Geographic Area
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Cardiovascular and Metabolic Disease Products, 2008
- Major Virology Products, 2008
- Major Neuroscience Products, 2008
- Major Oncology Products, 2008
- Major Immunology Products, 2008
- Major North American Subsidiaries
- Major European Subsidiaries
- Major South American Subsidiaries
- Major Asia/Pacific Region Subsidiaries
INDEX OF CHARTS
- Capital Expenditure By Business Segment, 2008
- Sales By Business Segment, 2008
- Operating Income By Business Segment
- Sales By Geographic Area (Origin)
- Sales of Top Ten Products (2003A-2013E)
- Top Selling Products, 2008
- Avapro/Avalide Sales (2003A-2013E)
- Plavix/Iscover Sales (2003A-2013E)
- Apixaban Sales (2011E-2015E)
- Onglyza Sales (2009E-2012E)
- Baraclude Sales (2005A-2013E)
- Reyataz Sales (2003A-2013E)
- Sustiva Sales (2003A-2013E)
- Abilify Sales (2003A-2013E)
- Erbitux Sales (2004A-2014E)
- IxempraSales (2007E-2015E)
- Sprycel Sales (2006A-2012E)
- Ipilimumab Sales (2009E-2012E)
- Orencia Sales (2006A-2013E)
- Belatacept Sales (2009E-2015E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
Related Report
|
View Cart
